Skip to content
10-Q

Quarterly Report

Forte Biosciences, Inc. FBRX

0000950170-25-108889

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 11, 2025 12.43M sh
Capex Q2 2025 · Jun 30, 2025 $61K
Capex Q2 2025 · Jun 30, 2024 $6K
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$20.42M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$12.6M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $106.14M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $22.24M
Stockholders Equity Q2 2025 · Jun 30, 2025 $98.61M
Stockholders Equity Q2 2025 · Mar 31, 2025 $38.43M
Stockholders Equity Q2 2025 · Dec 31, 2024 $52.48M
Stockholders Equity Q2 2025 · Jun 30, 2024 $16.96M
Stockholders Equity Q2 2025 · Mar 31, 2024 $28.69M
Stockholders Equity Q2 2025 · Dec 31, 2023 $35.31M
Current Liabilities Q2 2025 · Jun 30, 2025 $9.17M
Current Liabilities Q2 2025 · Dec 31, 2024 $9.08M
Current Assets Q2 2025 · Jun 30, 2025 $107.62M
Current Assets Q2 2025 · Dec 31, 2024 $61.35M
Total Assets Q2 2025 · Jun 30, 2025 $107.78M
Total Assets Q2 2025 · Dec 31, 2024 $61.56M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.96
Eps Diluted Q2 2025 · Jun 30, 2025 −$2.32
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$6.78
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$10.81
Eps Basic Q2 2025 · Jun 30, 2025 −$0.96
Eps Basic Q2 2025 · Jun 30, 2025 −$2.32
Eps Basic restated Q2 2025 · Jun 30, 2024 −$6.78
Eps Basic restated Q2 2025 · Jun 30, 2024 −$10.81
Sga Expense Q2 2025 · Jun 30, 2025 $2.96M
Sga Expense Q2 2025 · Jun 30, 2025 $6.39M
Sga Expense Q2 2025 · Jun 30, 2024 $7.08M
Sga Expense Q2 2025 · Jun 30, 2024 $10.53M
Net Income Q2 2025 · Jun 30, 2025 −$11.25M
Net Income Q2 2025 · Jun 30, 2025 −$26.91M
Net Income Q2 2025 · Mar 31, 2025 −$15.66M
Net Income Q2 2025 · Jun 30, 2024 −$12.51M
Net Income Q2 2025 · Jun 30, 2024 −$19.93M
Net Income Q2 2025 · Mar 31, 2024 −$7.42M
Operating Income Q2 2025 · Jun 30, 2025 −$11.58M
Operating Income Q2 2025 · Jun 30, 2025 −$27.7M
Operating Income Q2 2025 · Jun 30, 2024 −$12.82M
Operating Income Q2 2025 · Jun 30, 2024 −$20.62M
Short Term Investments Q2 2025 · Dec 31, 2024 $36.12M